Showing results (201-210 of 212) with videos related to
Sort By:
Pageof 22
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.Cancer Research|March 21, 2020
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR MutationsJacqueline H Starrett, Alexis A Guernet, Maria Emanuela Cuomo, et al.Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.Molecular Cancer|July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitorsJordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.Journal of Medicinal Chemistry|September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated ResistanceM Raymond V Finlay, Peter Barton, Sue Bickerton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIsNicola Colclough, Kan Chen, Peter Johnström, et al.Cancer Discovery|March 8, 2024
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug CombinationsAzadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, et al.Pageof 22